JAK inhibitors have also been proposed as COVID-19 potential treatments based on their ability to prevent the phosphorylation of signal transducer and activator of transcription (STAT) proteins involved in the immune activation and inflammation (Babon et al., 2014), such as cellular response to proinflammatory cytokines like IL-6 (Zhang et al., 2020b). This evidence concerns the gene SOAT1 and COVID-19.